Barinthus Biotherapeutics PLC - ADR (BRNS) Stock Price & News

Barinthus Biotherapeutics plc is a biotechnology company developing immunotherapies for infectious diseases, cancer and autoimmune diseases such as hepatitis B, HPV and prostate cancer. Formerly known as Vaccitech plc, in November 2023 the company announced that it had renamed itself to Barinthus Biotherapeutics plc. As of 2024, the company employs more than 100 people. Wikipedia

About Barinthus Biotherapeutics PLC - ADR

CEO-

Employees14

Founded2016

Headquarters-

SectorBiotechnology

Websitebarinthusbio.com

Analyst	Recommendation	Action	Price target	Projected	Date
Yi Chen H.C. Wainwright	Buy	Reiterated	-	-	08/25/2026
James Molloy Alliance Global Partners	Buy	Maintained	$6.00	+710.7%	08/06/2026

All values in USD	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Revenue	-	-	-	-
Cost of goods sold	-308.00K	374.00K	-	3.92M
Cost of revenue	-308.00K	374.00K	-	3.92M
Research and development expenses	5.46M	3.44M	3.44M	-42.00K
Total research and development expenses	-	-	-	-
Selling, general, and admin expenses	5.15M	1.50M	2.38M	7.03M
Operating expense	10.53M	4.51M	5.78M	6.98M
Total operating expenses	10.23M	4.88M	5.78M	10.91M
Operating income	-10.23M	-4.88M	-5.78M	-10.91M
Other non operating income	-275.00K	-104.00K	39.00K	26.00K
EBT including unusual items	-14.64M	-11.16M	-5.55M	-10.62M
EBT excluding unusual items	-10.04M	-4.59M	-5.40M	-10.55M
Income tax expense	-71.00K	-57.00K	-16.00K	-23.00K
Effective tax rate	0.48%	0.51%	0.29%	0.22%
Other operating expenses	-72.00K	-434.00K	-46.00K	-5.00K
Net income	-14.57M	-11.09M	-5.53M	-10.58M
Net profit margin	-	-	-	-
Earnings per share	-0.24	-0.27	-0.14	-0.26
Interest and investment income	472.00K	406.00K	350.00K	343.00K
Interest expense	-13.00K	-13.00K	-13.00K	-14.00K
Net interest expenses	459.00K	393.00K	337.00K	329.00K
Depreciation and amortization charges	-	-	-	-
EBITDA	-10.12M	-4.57M	-5.52M	-10.69M
Gain or loss from assets sale	-68.00K	104.00K	-38.00K	-32.00K

Finance

Ask anything